Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Total Voting Rights

3 Jul 2023 07:00

RNS Number : 6457E
Cambridge Cognition Holdings PLC
03 July 2023
 

3 July 2023

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Total Voting Rights

 

 

Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, announces that pursuant to its block admission facility, details of which were announced on 21 March 2023, it has recently issued 37,444 new ordinary shares in the Company in satisfaction of the exercise of employee share options. Accordingly, as at 30 June 2023 the Company has 34,852,833 ordinary shares in issue.

 

There are no shares held in treasury therefore the total number of voting rights in the Company is 34,852,833. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in Cambridge Cognition under the FCA's Disclosure and Transparency Rules.

 

The Company intends to notify on a monthly basis when there are changes to the issued share capital of the Company, and these monthly figures may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company, under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Enquiries:

 

Cambridge Cognition Holdings Plc 

Matthew Stork, Chief Executive Officer 

Stephen Symonds, Chief Financial Officer 

Tel: 012 2381 0700 

press@camcog.com 

 

Panmure Gordon (UK) Limited (NOMAD and Joint Broker) 

Freddy Crossley / Emma Earl  

Rupert Dearden 

 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

Dowgate Capital Limited (Joint Broker) 

David Poutney / James Serjeant 

Tel: 020 3903 7715 

 

 

IFC Advisory Ltd (Financial PR and IR) 

Tim Metcalfe / Graham Herring / Zach Cohen 

 

Tel: 020 3934 6630 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRUPUAUMUPWGGG
Date   Source Headline
1st Jun 20267:00 amRNS-RCOG to present at Mello 2026
28th May 20261:15 pmRNSLaunch of brain health study with Oura
21st May 20262:50 pmRNSResult of AGM
24th Apr 20263:16 pmRNSPosting of Annual Report & Notice of AGM
13th Apr 20267:00 amRNSResults for the year ended 31 December 2025
7th Apr 20267:01 amRNSNotice of Results
7th Apr 20267:00 amRNSAppointment of Nominated Adviser and Joint Broker
1st Apr 20267:00 amRNSBlock Listing Return
11th Mar 20267:00 amRNSMonument Therapeutics MT1988 First Patient Dosed
11th Mar 20267:00 amRNSMonument Therapeutics MT1988 First Patient Dosed
16th Feb 20267:00 amRNSCommercialisation Agreement
9th Feb 20267:00 amRNSChange of Joint Broker
19th Jan 20267:00 amRNSTrading Update
5th Nov 20257:01 amRNSChange of Auditor
5th Nov 20257:00 amRNSBoard Updates
1st Oct 20257:00 amRNSBlock Listing Return
29th Sep 20257:00 amRNSExercise of Options and Total Voting Rights
26th Sep 20259:59 amRNSHolding(s) in Company
8th Sep 20257:00 amRNSHolding(s) in Company
5th Sep 20252:51 pmRNSHolding(s) in Company
5th Sep 202512:04 pmRNSHolding(s) in Company
2nd Sep 20255:21 pmRNSHolding(s) in Company
1st Sep 202510:58 amRNS-RInvestor Presentation via Investor Meet Company
28th Aug 202510:45 amRNS£1.12m Placing & Subscription, TVR & PDMR Dealings
28th Aug 20257:01 amRNSChanges to Board and Management
28th Aug 20257:00 amRNSInterim Results
19th Aug 202510:10 amRNS-RMonument Therapeutics Partnership with FNIH
12th Aug 20257:00 amRNSLaunch of Speaker Identification Solution
31st Jul 20257:00 amRNSTrading update for period ended 30 June 2025
27th Jun 202512:27 pmRNSResult of AGM
24th Jun 20257:00 amRNS-RMonument Therapeutics Success in Phase I Results
4th Jun 20257:00 amRNSNotice of AGM
6th May 20255:59 pmRNSHolding(s) in Company
1st May 20257:00 amRNSPreliminary Unaudited Results
24th Apr 20257:00 amRNSNotice of Results and Investor Presentation
10th Apr 20257:00 amRNSContract Win
7th Apr 202510:24 amRNSHolding(s) in Company
3rd Apr 20257:00 amRNSContract Win
1st Apr 20257:00 amRNSBlock Listing Return
6th Mar 20257:00 amRNS-RCANTAB® used for major global brain health study
18th Feb 20257:00 amRNS-RCambridge Cognition submits FDA Letter of Intent
7th Feb 20257:00 amRNSBoard Appointment
21st Jan 20257:00 amRNSLaunch of in-house rater training service
16th Jan 20257:00 amRNSExpanded partnership with Actinogen
27th Dec 20243:34 pmRNSDirector/PDMR Share Purchases
23rd Dec 20244:02 pmRNSDirector/PDMR Share Purchases
16th Dec 20249:20 amRNSDirector/PDMR Share Purchases
10th Dec 20247:00 amRNSTrading Update
18th Nov 20244:02 pmRNSHolding(s) in Company
6th Nov 20247:00 amRNSMonument Therapeutics secures £1m investment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.